Introduction
Life-long continuous androgen suppression (CAS) remains the mainstay of systemic treatment for symptomatic patients with metastatic or locally advanced prostate cancer. 1 The increasing availability of PSA testing for patients with prostatic symptoms and in primary carè health checks' is leading to patients spending longer time on treatment. Even in this setting CAS is only palliative not curative. The late effects of CAS includes loss of bone density 2 and anemia. 3 With increased use of PSA testing these late effects are becoming an even more important problem than the immediate effects of impotence and hot ushes. Reducing the morbidity and improving the cost ef®ciency of CAS is rapidly becoming a major health issue, particularly in the Western world.
In the past, several studies have addressed the issue as to whether it is safe to defer treatment until the patient develops symptoms needing treatment. 1 Although initially thought to be safe, the deferred option has been associated with an increase risk of mortality and serious complication of the disease such as fractures and paraplegia. 4 Furthermore the bene®ts of early treatment have tended to be more apparent in M0 than in M patients. 4 M0 patients live the longest and have fewer symptoms from the disease and more problems from the side effects of treatment. Furthermore the development of androgen resistance is still the ultimate cause of death in the majority of cases.
These observations have led, in the last 5 y, to increased interest in the use of intermittent hormone therapy. In these studies therapy has been used for a period to relieve symptoms and then stopped, provided there has been normalization of PSA, and only restarted when PSA reached a certain level (for review see Bruchovsky et al 5 and Gleave et al 6 ). The rationale for this was that chronic growth factor de®ciency favoured the growth of cells which had a lower degree of growth factor dependence. Given the increasing work on the use of growth factor receptors as targets for new cancer treatments, clarifying this issue will be of considerable importance not only for sex hormone dependant cancers. Laboratory data that supported this view came from the demonstration that cells at relapse had either an over expressed androgen receptor that needed less androgen to grow 7 or a mutated androgen receptor that was stimulated not blocked by the anti-androgen used as therapy. 8 In two of four animal models of endocrine sensitive cancer there was a doubling in survival when intermittent therapy was used. 9 ± 12 Although there has so far been no randomized trial, a recent review reported that more than 400 patients had been treated in this way. The average time on treatment was 9 months on and time off was also 9 months. Patients had an average of three cycles of therapy before becoming resistant. As yet there has not been a universal agreement on optimum criteria for stopping and starting treatment and this has slowed the setup of randomized trials.
During the past 5 y, this unit has been undertaking a phase I/II pilot study that has attempted to investigate some of these unresolved variables in designing a standard for use of hormone therapy intermittently. 13, 14 This paper summarizes the current data from these studies that are currently being written up for publication (Farrugia, in preparation).
Results
An additional 30 patients have been recruited since the original 20 reported. 14 There were 17 who were M and/or N and 33 who were M0. This later group consisted of seven M0 patients in relapse after radiation, 11 M0 patients who had responded to combined hormones and radiation and 15 M0 patients who responded to hormones alone given for locally advanced disease. Overall 57% of the 50 patients were progression-free off hormones at 12 months and 40% at 2 y . Forty progressed on observation and received a second cycle of treatment. All except four responded a second time. Ten subsequently developed hormone resistance while continuing on treatment. Sixteen responders then proceeded to a second cycle off treatment (Table 1) , two of whom remain off treatment. One died of a stroke off treatment and 4 started a third cycle. Of the 40 who restarted, 95% remained alive at 12 months, 86% at 2 y and 71% at 3 y after restarting hormones.
Overall 92% of all 50 patients entered into the study were alive at 3 y from the start of their ®rst cycle of treatment.
Subgroup analysis
There was a considerable degree of heterogeneity and selection in the patients referred for this study. Insuf®cient numbers are present to allow sub group analysis. However, they offer some insight into the variables that might need to be taken into consideration when designing prospective randomized trials. The relapse rate at 12 months has been used as the indicator and using this parameter M0 patients was somewhat different from M and N patients (70% vs 37%). In addition duration of hormone treatment before stopping, age and PSA level prior to primary hormone therapy in¯uenced time to PSA relapse. PSA b 100 pretreatment had 50% progression free of hormones at 12 months vs 71% in those whose pretreatment PSA was less than 100. There was no obvious difference in time to retreatment for monotherapy vs MAB.
Impact of radiation
There was a suggestion of more prolonged PSA control in a small group of four patients given radiation concurrently with hormones after their 2nd cycle off hormones. This has been given because these patients had had a short time off therapy during their initial hormone therapy cycles (ie 2 vs 20, 2 7 vs 26, 13 vs 22 months, see Table 2 ).
Discussion
A substantially larger number of cases with multivariate analysis would be required to be certain about the independent signi®cance of all the variables analysed in this study. Nonetheless they do highlight a number of factors that need to be considered in de®ning the best strategy for use of hormone therapy intermittently. There were trends to longer relapse free survival in older patients, those with the longer periods on treatment before hormone therapy was stopped and in those who had been irradiated, whether as a planned part of initial induction or as part of subsequent cycles of hormone therapy. These could be explained on the basis that they were situations in which it might be expected that it would take longer for the levels of testosterone to recover. There is an increasing consensus view from more than 400 M cases reported in a recent literature review 5 that from 6 ± 9 months on hormone therapy is followed by a period of 6 to 9 months off treatment although there is 20% subset with prolonged relapse free survival. This observation would ®t with data on the rate of decline of PSA after hormone therapy, which shows a biphasic curve with the ®rst phase lasting one month and the second reaching the maximum response after about 9 months. 15 Furthermore, as the average patient remains hormone sensitive for three cycles they are surviving in excess of 4 y. This is nearly double the expected survival for M patients. Despite this emerging consensus and the relatively large numbers of patients treated in phase I/II studies, it is now more than 12 y since the ®rst US report 16 on the use of intermittent hormone therapy and 5 y since our ®rst report in the UK. 13 However, worldwide, the overwhelming majority of hormone therapy is still given continuously. As emphasized in the introduction, it is increasingly being used at an earlier stage in the natural history because PSA testing is detecting the disease more than 5 y earlier than it would present clinically. 17 There is now a European and American randomized trial actively recruiting, though it is only for M patients. Furthermore, only patients receiving anti-androgen plus LHRH are eligible. Despite this, it is important that everything possible is done to encourage recruitment to complete these trials. In the mean time it will also be important to develop more meaningful animal models, as this would give a quicker answer to the critical issue of whether there is prolongation of survival by this strategy. So far in two of four models studied there has been prolongation of survival while in two the survival was, if anything, worse. 9 ± 12 The latter two studies both used the Dunning rat prostate cancer model and gave hormone treatment for 7 ± 14 days every 28 days for a tumour that, under continuous suppression, took 112 days to become hormone independent, ie induction time was only 6% of the time the tumour remains hormone sensitive. As our data suggests that the best duration of induction is 6 ± 9 months and this represents between 25 ± 33% of the time patients remain hormone sensitive it is possible that there could be prolonged survival by this strategy. Given the selected nature of patients treated in this study it would be dif®cult to draw conclusions from the survival data. However despite 49% of our patients having metastatic disease or failed primary therapy, the overall survival at 3 y of 92% for the patients reported is at least as good as that reported for M0 patients in the immediate therapy arm of the recent MRC study 4 and the recently reported casodex continuous monotherapy study.
There is one other issue raised by the emerging data from use of hormone therapy intermittently. This is that the periods off treatment which are between 6 and 9 months in 50% of patients are very predictable. As demonstrated in Table 3 they offer a surrogate endpoint with a shorter timescale than survival or time to hormone resistance that could be used for earlier investigation of new approaches to therapy of prostate cancer. Studies of genetherapy, tumour vaccines and antisense therapy against critical targets in tumour growth could bene®t from such an approach. One of the most interesting targets in this respect is bcl-2. This is known to be upregulated as endocrine sensitive cells become hormone resistant. 18 Furthermore, animal models have demonstrated prolongation of hormone control using antisense bcl-2. 19 To date there has only been clinical studies using antisense bcl-2 in patients who have become totally 21 There has only been one exception and that was in a small trial in breast cancer. Patients who had demonstrated that their tumour was hormone sensitive were randomized to control or immunotherapy. 22 In that study, which only entered less than 40 patients, there was a signi®cant difference in 3 y relapse free survival of 47% vs 15%. Hormone sensitivity is the norm of the prostate cancer precursor cell. Demonstration of hormone sensitivity could be considered as a marker of a better differentiated early cancer. BCG studies in bladder cancer clearly demonstrate that it is early cases that are more likely to bene®t from immunotherapy. 21 It is therefore surprising that there has been no attempt to repeat this observation in 15 y since it was ®rst made. Evidence that castration induces regeneration of the thymus 23 and a peripheral blood lymphocytosis 24 is another observation that justi®es combining immunotherapy and hormone therapy.
The issue of androgen sensitivity being a marker of a clonally less mutated cancer cell raises one ®nal issue that needs to be considered in future studies of intermittent hormone therapy. This is the question of how early in the natural history hormone therapy should be used. There is increasing evidence from studies of intermittent hormone therapy that there was a signi®cant minority who had prolonged survival off treatment. Were the combination of hormone therapy and vaccines to increase this proportion it might then be possible to consider use of hormone therapy earlier in the natural history of the disease. It might even be acceptable as a treatment for precancerous lesions such as prostatic intra-epithelial neoplasia. 6, 25 The recently reported dog model 26 provides a particularly interesting way of testing such a hypothesis.
